1994
DOI: 10.1056/nejm199409293311304
|View full text |Cite
|
Sign up to set email alerts
|

A Comparison of Budesonide with Prednisolone for Active Crohn's Disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

9
305
1
6

Year Published

1998
1998
2015
2015

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 547 publications
(328 citation statements)
references
References 13 publications
9
305
1
6
Order By: Relevance
“…Comparable clinical e ects have been reported from placebocontrolled and active-comparator trials, with approximately 50 -70 % of patients achieving a clinical remission over 8 -17 weeks receiving the equivalent of prednisone, 0.5 -0.75 mg / kg (or 40 mg) daily (91,117,121) . Higher doses of prednisone (1 mg / kg) or methyl prednisolone (1 mg / kg) have had somewhat higher response rates of 80 -90 % (ref.…”
Section: Mild To Moderate Active Diseasementioning
confidence: 84%
“…Comparable clinical e ects have been reported from placebocontrolled and active-comparator trials, with approximately 50 -70 % of patients achieving a clinical remission over 8 -17 weeks receiving the equivalent of prednisone, 0.5 -0.75 mg / kg (or 40 mg) daily (91,117,121) . Higher doses of prednisone (1 mg / kg) or methyl prednisolone (1 mg / kg) have had somewhat higher response rates of 80 -90 % (ref.…”
Section: Mild To Moderate Active Diseasementioning
confidence: 84%
“…Budesonide is a highly potent steroid, indicated for the treatment of asthma and gastrointestinal disorders because of a very low bioavailability when absorbed through mucosal surfaces that minimizes systemic side effects [15,16]. Current knowledge regarding the effect of topical budesonide treatment in oral cGVHD is not sufficient.…”
Section: Introductionmentioning
confidence: 99%
“…Side-effects were much fewer in patients given budesonide CR than prednisolone, as was adrenal suppression assessed by measurement of plasma cortisol levels [14] . When evaluated for maintenance of remission over 12 months in CD, budesonide CR delayed the onset of relapse when compared to placebo, but overall relapse rates at 1 year (60-70%) were, disappointingly, not improved [16,17] .…”
Section: New Formulations and Applications Of Existing Drugsmentioning
confidence: 99%
“…When given in an oral controlled ileal release (CR) formulation to patients with active ileocaecal CD, budesonide was not significantly less effective than prednisolone in inducing remission in one study [14] and substantially better than placebo in another [15] . Side-effects were much fewer in patients given budesonide CR than prednisolone, as was adrenal suppression assessed by measurement of plasma cortisol levels [14] .…”
Section: New Formulations and Applications Of Existing Drugsmentioning
confidence: 99%